Child, parent, and service predictors of psychotropic polypharmacy among adolescents and young adults with an autism spectrum disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 9, 2014, Pages 486-493

  Lake, Johanna K ^a,b   Weiss, Jonathan A ^c   Dergal, Julie ^a   Lunsky, Yona ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ARTICLE; ASPERGER SYNDROME; AUTISM; CHILD; CHILD HEALTH CARE; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL INFORMATION; PARENT BURDEN; PARENTAL ATTITUDE; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; POLYPHARMACY; PREDICTION; WELLBEING; CHILD DEVELOPMENT DISORDERS, PERVASIVE; PARENT; PSYCHOLOGY; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PARENTS; POLYPHARMACY; PSYCHOTROPIC DRUGS; YOUNG ADULT;

EID: 84911481236     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2014.0011     Document Type: Article

References (62)

1. Aman MG, Lam KSL, Collier-Crespin A: Prevalence and patterns of use of psychoactive medicines among individuals with autism in the autism society of Ohio. J Autism Dev Disord 33:527-534, 2003.
2. Aman MG, Lam KSL, Van Bourgondien ME: Medication patterns in patients with autism: Temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 15:116-126, 2005.
3. Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall KL, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A: Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 48:1143-1154, 2009.
4. Arnsten A, Scahill L, Findling R: Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Emerging concepts from new data. J Child Adolesc Psychopharmacol 17:393-406, 2007.
5. Blumberg SJ, Bramlett MD, National Center for Health Statistics, Kogan MD, Maternal and Health Bureau, Schieve LA, National Center on Birth Defects and Developmental Disabilities, Jones JR, Lu MC, Maternal and Child Health Bureau: Changes in prevalence of parent-reported autism spectrum disorder in school-aged US children: 2007 to 2011-2012. Natl Health Statist Report 65:1-11, 2013.
6. Bradley E, Lofchy J: Learning disability in the accident and emergency department. Adv Psychiatry 11:345-357, 2005.
7. Brooks WT, Benson BA: The validity of the social communication questionnaire in adults with intellectual disability. Res Autism Spect Dis 7:247-255, 2013.
8. Brosnan J, Healy O: A review of behavioral interventions for the treatment of aggression in individuals with developmental disabilities. Res Dev Disabil 32:437-446, 2011.
9. Cadman T, Eklund H, Howley D, Hayward H, Clarke H, Findon J, Xenitidis K, Murphy D, Asherson P, Glaser K: Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. J Am Acad Child Adolesc Psychiatry 51:879-888, 2012.
10. Campbell JM: Efficacy of behavioral interventions for reducing problem behavior in persons with autism: A quantitative synthesis of single-subject research. Res Dev Disabil 24:120-138, 2003.
11. Centers for Disease Control and Prevention: Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR 61:1-19, 2012.
12. Centers for Disease Control and Prevention, National Center for Health Statistics: State and Local Area Integrated Telephone Survey. 2011-2012 National Survey of Children's Health Frequently Asked Questions. April 2013. Available at http://www.cdc.gov/nchs/slaits/nsch.htm. Last accessed April 22, 2014.
13. Chen H, Patel A, Sherer J, Aparasu R: The definition and prevalence of pediatric psychotropic polypharmacy. Psychiatr Serv 62:1450-1455, 2011.
14. Coury DL, Anagnostou E, Manning-Courtney P, Reynolds A, Cole L, McCoy R, Whitaker A, Perrin JM: Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 130:S69-S76, 2012.
15. Esbensen AJ, Greenberg JS, Seltzer MM, Aman MG: A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord 39:1339-1349, 2009.
16. Foxx RM: Applied behavior analysis treatment of autism: The state of the art. Child Adolesc Psychiatr Clin N Am 17:821-834, 2008.
17. Frazier TW, Youngstrom EA, Haycook T, Sinoff A, Dimitriou F, Knapp J, Sinclair L: Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder. J Child Adolesc Psychopharmacol 20:167-177, 2010.
18. Goren JL, Meterko M, Williams S, Young GJ, Baker E, Chou CH, Kilbourne AM, Bauer MS: Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv 64:527-533, 2013.
19. Harris E, Sobero M, Kogan JN, Schuster J, Stein BD: Concurrent mental health therapy among medicaid-enrolled youths starting antipsychotic medications. Psychiatr Serv 63:351-356, 2012.
20. Hassiotis A, Robotham D, Canagasabey A, Romeo R, Langridge D, Blizard R, Murad S, King M: Randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behavior in adults with intellectual disabilities. Am J Psychiatry 166:1278-1285, 2009.
21. Howlin P, Moss P: Adults with autism spectrum disorders. Can J Psychiatry 57:275-283, 2012.
22. Hsia Y, Wong AY, Murphy DG, Simonoff E, Buitelaar JK, Wong IC: Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology 23:999-1009, 2014.
23. Kaplan G, McCracken JT: Psychopharmacology of autism spectrum disorders. Pediatr Clin North Am 59:175-187, 2012.
24. Khanna R, Jariwala K, West-Strum D: Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme. J Intellect Disabil Res 57:161-171, 2012.
25. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, Singh GK, Strickland BB, Trevathan E, van Dyck, PC: Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 124:1395-1403, 2009.
26. Kowatch RA, Youngstrom EA, Horwitz S, Demeter C, Fristad MA, Birmaher B, Axelson D, Ryan N, Frazier TW, Arnold LE, Young AS, Gill M, Findling RL: Prescription of psychiatric medications and polypharmacy in the LAMS cohort. Psychiatr Serv 64:1026-1034, 2013.
27. Kring SR, Greenberg JS, Seltzer MM: Adolescents and adults with autism with and without co-morbid psychiatric disorders: Differences in maternal well-being. J Ment Health Res Intellect Disabil 1:53-74, 2008.
28. Lake JK, Balogh R, Lunsky Y: Polypharmacy profiles and predictors among adults with autism spectrum disorders. Res Autism Spect Dis 6:1142-1149, 2012.
29. Langworthy-Lam KS, Aman MG, Van Bourgondien ME: Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol 12:311-321, 2002.
30. Lawton MP, Kleban MH, Moss MA, Rovine M, Glicksman A: Measuring caregiving appraisal. J Gerontol B Psychol Sci Soc Sci 44:61-71, 1989.
31. Lawton MP, Moss M, Hoffman C, Perkinson M: Two transitions in daughters' caregiving careers. Gerontologist 40:437-448, 2000.
32. Lin L: Factors associated with caregiver burden and maternal pessimism in mothers of adolescents with an autism spectrum disorder in Taiwan. Occup Ther Int 18:96-105, 2010.
33. Logan SL, Nicholas JS, Carpenter LA, King LB, Garrett-Mayer E, Charles JM: High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance network. Ann Epidemiol 22:1-8, 2012.
34. Lunsky Y, Balogh R, Cairney J: Predictors of emergency department visits by persons with intellectual disability experiencing a psychiatric crisis. Psychiatr Serv 63:287-290, 2012.
35. Lunsky Y, Elserafi J: Antipsychotic medication prescription patterns in adults with developmental disabilities who have experienced a psychiatric crisis, Res Dev Disabil 33:32-38, 2012.
36. Mackintosh VH, Goin-Kochel RP, Myers BJ: "What do you like/dislike about the treatments you're currently using?": A qualitative study of parents of children with autism spectrum disorders. Focus Autism Other Dev Disabl 27:51-60, 2012.
37. Mandell DS, Morales KH, Marcus SC, Stahmer A, Doshi J, Polsky DE: Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 121:441-448, 2008.
38. Matson JL, Hess JA: Psychotropic drug efficacy and side effects for persons with autism spectrum disorders. Res Autism Spect Dis 5:230-236, 2011.
39. Mazurek MO, Shattuck PT, Wagner M, Cooper BP: Prevalence and correlates of screen-based media use among youths with autism spectrum disorders. J Autism Dev Disord 42:1757-1767, 2011.
40. McCracken JT: Safety issues with drug therapies for autism spectrum disorders. J Clin Psychiatry 66:32-37, 2005.
41. Montes G, Halterman JS: Psychological functioning and coping among mothers of children with autism: A population-based study. Pediatrics 119:e1040-e1046, 2007.
42. Memari AH, Ziaee V, Beygi S, Moshayedi P, Mirfazeli FS: Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: Perspective from a developing country. Res Dev Disabil 33:563-569, 2012.
43. Myers SM: The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 8:1579-1603, 2007.
44. Myers S, Plauche Johnson C: Management of children with autism spectrum disorders. Pediatrics 120:1162-1182, 2007.
45. Oswald DP, Sonenklar NA: Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 17: 348-355, 2007.
46. Perkins EA, Berkman KA: Into the unknown: Aging with autism spectrum disorders. Am J Intellect Dev Disabil1 17:478-496, 2012.
47. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ: Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14:233-241, 2004.
48. Posey DJ, Stigler KA, Erickson CA, McDougle CJ: Antipsychotics in the treatment of autism. J Clin Invest 118:6-14, 2008.
49. Pruchno RA, McMullen WF: Patterns of service utilization by adults with developmental disability: Type of service makes a difference. Am J Ment Retard 109:362-378, 2004.
50. Reiss S, Aman MG: The International Consensus Handbook: Psychotropic Medication and Developmental Disabilities. Columbus, OH: The Ohio State University Nisonger Center; 1998.
51. Rosenberg RE, Mandell DS, Farmer JE, Law JK, Marvin AR, Law PA: Psychotropic medication use among children with autism spectrum disorders enrolled in a National Registry, 2007-2008. J Autism Dev Disord 40:342-351, 2010.
52. Schall C: A consumer's guide to monitoring psychotropic medication for individuals with autism spectrum disorders. Focus Autism Other Dev Disabil 17:229-235, 2002.
53. Schieve LA, Blumberg SJ, Rice C, Visser SN, Boyle C: The relationship between autism and parenting stress. Pediatrics 119:S114-S121, 2007.
54. Schubart JR, Camacho F, Leslie D: Psychotropic medication trends among children and adolescents with autism spectrum disorder in the Medicaid program. Autism 18:631-637, 2013.
55. Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T, Azocar F, Jain A: Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics 132:833-840, 2013.
56. Stigler KA, Potenza MN, Posey DJ, McDougle CJ: Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Pediatr Drugs 6:33-44, 2004.
57. Sullivan WF, Berg JM, Bradley E, Cheetham T, Denton R, Heng J, Hennen B, Joyce D, Kelly M, Korossy M, Lunsky Y, McMillan S: Primary care of adults with developmental disabilities: Canadian consensus guidelines. Can Fam Physician 57:541-553, 2011.
58. Tsakanikos E, Costello H, Holt G, Sturmey P, Bouras N: Behaviour management problems as predictors of psychotropic medication and use of psychiatric services in adults with autism. J Autism Dev Disord 37:1080-1085, 2007.
59. Weiss JA, Lunsky Y: The Brief Family Distress Scale: A measure of crisis in caregivers of individuals with autism spectrum disorders. J Child Fam Stud 20:521-528, 2011.
60. Weiss JA, Lunsky Y, Gracey C, Canrinus M, Morris S: Emergency psychiatric services for individuals with intellectual disabilities: Caregivers' perspectives. J Appl Res Intellect 22:354-362, 2009.
61. Witwer A, Lecavalier L: Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol 15:671-681, 2005.
62. Xiong N, Yang L, Yu Y, Hou J, Li J, Liu H, Zhang Y, Jiao Z: Investigation of raising burden of children with autism, physical disability and mental disability in China. Res Dev Disabil 31:306-311, 2011.